Physician profile
Brett Earnest
NPI 1134389711
$2,503.03
in general payments reported to CMS, 2019-2025
24 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $128 · 2021: $161 · 2022: $342 · 2023: $332 · 2024: $676 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.12 | 2019-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $505.37 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $143.53 | 2022-2025 | Rybelsus, Ozempic |
| Collegium Pharmaceutical, INC. | $139.32 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $134.34 | 2024 | |
| Merck Sharp & Dohme LLC | $104.54 | 2021-2025 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Dentsply Sirona INC | $100.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.29 | 2025 | |
| Glaxosmithkline, LLC. | $82.13 | 2021-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $75.32 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $71.72 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.75 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $41.84 | 2022-2024 | Airsupra |
| Tris Pharma INC | $38.51 | 2024 | Dyanavel Xr |
| Abbott Laboratories | $34.79 | 2025 | Afinion 2 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $32.68 | 2025 | Senza |
| Nevro Corp. | $27.73 | 2024 | Senza |
| Pfizer INC. | $26.23 | 2024 | |
| Exact Sciences Corporation | $20.03 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.39 | 2021 | |
| Cranial Technologies, INC | $16.88 | 2021 | |
| Owp Pharmaceuticals, INC. | $16.02 | 2025 | Subvenite |
| Supernus Pharmaceuticals, INC. | $14.61 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $13.89 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Earnest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.